Allogene Therapeutics, Inc. (ALLO) vs CorMedix Inc (CRMD)

Allogene Therapeutics, Inc. and CorMedix Inc are both Biotechnology companies. Allogene Therapeutics, Inc. and CorMedix Inc are of similar size ($608.0M and $594.2M). Allogene Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; CorMedix Inc trades at 3.3×. Allogene Therapeutics, Inc. grew revenue faster over the last twelve months: 7,613.1% against 280.5%. CorMedix Inc has the higher net margin (40.5% vs −3,517.4%) and the higher return on invested capital (38.8% vs −108.8%). Across the 17 metrics below, CorMedix Inc leads on 12 and Allogene Therapeutics, Inc. on 5.

Valuation

Metric ALLO CRMD Biotechnology median
P/E n/m 3.26 7.88
P/S 115.35 1.33 11.47
P/B 1.24 1.34 2.52
Price to free cash flow n/m 2.46 21.16
EV/EBITDA n/m 1.99 0.74
EV/Sales 44.66 1.09 10.73
Earnings yield (40.61%) 30.70% (28.84%)
Free cash flow yield (18.90%) 40.67% (23.03%)

Profitability

Metric ALLO CRMD Biotechnology median
Gross margin 100.00% 82.78% 65.16%
Operating margin (3,832.45%) 46.95% 0.00%
Net margin (3,517.41%) 40.49% 0.00%
Free cash flow margin (2,180.62%) 54.17% 0.00%
Return on equity (42.39%) 54.93% (57.72%)
Return on assets (32.43%) 32.36% (49.22%)
Return on invested capital (108.81%) 38.84% 0.00%

Growth

Metric ALLO CRMD Biotechnology median
Revenue growth (TTM) 7,613.11% 280.50% 5.64%
EPS growth (last fiscal year) 34.09% 780.00% —
Revenue growth, 5-year CAGR — 305.79% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALLO CRMD Biotechnology median
Debt to equity 0.00 0.32 0.00
Current ratio 10.72 2.56 4.73
Net debt to EBITDA 1.24 (0.02) 0.96

Dividend

Metric ALLO CRMD Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ALLO CRMD Biotechnology median
Market cap 594.24m 607.97m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack